Selecta Imm News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Selecta Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

31.10.2023 - WATERTOWN, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) - Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, . Seite 1

Peterg traberSelecta immCarsten brunnSelecta biosciences incSwedish orphan biovitrumBiologics license applicationChief medical officerChief executive officerSelecta biosciences chartElecta biosciences kursElecta biosciences aktie

Selecta Biosciences (SELB) Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi

Selecta Biosciences (SELB) Announces Transition of Manufacturing and Clinical Operations of ImmTOR for SEL-212 to Commercialization Partner Sobi
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Carsten brunnSelecta immPeterg traberSelecta biosciences incSelecta biosciencesSwedish orphan biovitrumBiologics license applicationChief medical officerChief executive officer

Selecta Biosciences in Deal to Transfer Manufacturing, Development Rights of Sel-212 Treatment

By Sabela Ojea Selecta Biosciences has agreed to transfer its manufacturing and development rights and remaining clinical operations for its Sel-212 medicine.

Selecta immSabela ojeaSelecta biosciencesSwedish orphanSwedish orphan biovitrumArticle normalBiotechnology servicesHealthcare life sciencesSobi skSe sobiLife sciences

FDA Approval of New Gout Drug Likely, Analyst Says

FDA Approval of New Gout Drug Likely, Analyst Says

United kingdomHong kongYun zhongSelecta immSelecta biosciencesStreetwise reportsDrug administrationAustralia limitedOr research restrictedSingapore pte ltdSelecta biosciences incExchange participantHorizon therapeutic krystexxaDoresa banningStreetwise reportSpecific regulatory disclosures

Sobi, Selecta: Phase 3 DISSOLVE Program Of SEL-212 In Chronic Refractory Gout Meets Primary Goal

Swedish Orphan Biovitrum AB or Sobi (SWTUY.PK), a specialised biopharmaceutical company, and Selecta Biosciences, Inc. (SELB) announced Tuesday positive topline results from Phase 3 DISSOLVE Program of SEL-212 in Chronic Refractory Gout.

Selecta biosciencesSelecta immSelecta biosciences incMore such health newsSwedish orphan biovitrumChronic refractoryGlobal studySelecta biosciencesChronic refractory goutHase 3 dissolve programIssolve programEl 212